The Benchmark Company
http://www.benchmarkcap.com/default.aspThe Benchmark Company, a full-service Broker Dealer, provides financial services to institutional and private clients. Its services include private placements, venture capital, M&A services, recapitalizations, divestitures & spin-offs, equity research as well as other financial services. The firm’s equity research division specializes in the media, energy, enterprise software, infrastructure software, and biotechnology & specialty pharmaceutical sectors.
View Older Stories View More Recent Stories
-
Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
-
Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
-
Updated Dial-In Information for Exchange Call with Contura Management
-
Contura Energy (CTRA) Announces Updated 2020 Guidance and Preliminary Q4 Results
-
Contura Announces Updated 2020 Guidance and Certain Preliminary, Unaudited Fourth Quarter 2019 Results
-
Nephros, Inc. (NEPH) Prices 937.5K Share Common Offering at $8/Sh
-
Nephros Announces Pricing of $7.5 Million Underwritten Offering of Common Stock
-
Nephros Announces Pricing of $7.5 Million Underwritten Offering of Common Stock
-
Nephros Announces Pricing of $7.5 Million Underwritten Offering of Common Stock
-
Exclusive: Temasek, Trustbridge target majority stake in WeWork China at $1 billion valuation – sources
-
cbdMD, Inc. Announces Closing of $18.4 Million Underwritten Public Offering of Common Stock
-
cbdMD, Inc. (YCBD) Prices 16M Share Common Offering at $1/Sh
-
cbdMD, Inc. Prices Underwritten Public Offering of Common Stock
-
The Benchmark Company Adds Industrial Research Team to Its Growing Platform
-
The Benchmark Company Adds Industrial Research Team to Its Growing Platform
-
AInnovation Raises Nearly US$60 million in Series B Financing to Deepen AI Application in Industries
-
Youngevity International, Inc. Announces Closing of $5.58 Million Public Offering of Series D Cumulative Redeemable Perpetual Preferred Stock
-
Youngevity International, Inc. Announces Pricing of $5.58 Million of Series D Cumulative Redeemable Perpetual Preferred Stock Offering
-
Hiperbaric Receives 2019 European Technology Award Recognizing Company's High Pressure Technology Innovation
-
Expedia CEO, CFO resign after clash over strategy with board
-
Edward Rubin Joins the Benchmark Company as Co-Head of Investment Banking
-
Edward Rubin Joins the Benchmark Company as Co-Head of Investment Banking
-
NAPCO Security Technologies to Attend the Benchmark Discovery Conference December 4, 2019
-
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
-
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
-
OSS to Present at Benchmark’s 8th Annual Discovery 1x1 Conference, December 4, 2019
-
OSS to Present at Benchmark’s 8th Annual Discovery 1x1 Conference, December 4, 2019
-
CNS Pharmaceuticals Announces Full Exercise of Over-Allotment Option
-
Harvard Bioscience to attend Benchmark’s 8th Annual Discovery One-on-One Conference
-
Harvard Bioscience to attend Benchmark’s 8th Annual Discovery One-on-One Conference
-
MTBC to Present at Benchmark, LD Micro Conferences in December
-
MTBC to Present at Benchmark, LD Micro Conferences in December
-
Titan Medical to Participate in Two Investment Conferences in December
-
Everspin to Participate at the Benchmark Discovery Conference on December 4
-
Adesto® to Participate at the Benchmark Discovery Conference on December 4
-
Youngevity International, Inc. Nasdaq YGYI, to Present at The Benchmark Company's 8th Annual Discovery 1x1 Investor Conference
-
Boxlight to Present at The Benchmark Company’s 8th Annual Discovery 1x1 Investor Conference on December 4, 2019
-
Taronis (TRNX) Completes $3.5 Million Convertible Preferred Offering
-
Taronis Completes $3.5 Million Convertible Preferred Offering
-
Taronis Completes $3.5 Million Convertible Preferred Offering
-
The Benchmark Company, LLC Announces Closing of Initial Public Offering of CNS Pharmaceuticals, Inc.
-
The Benchmark Company, LLC Announces Closing of Initial Public Offering of CNS Pharmaceuticals, Inc.
-
CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock
-
CNS Pharmaceuticals (CNSP) IPO Opens Flat
-
CNS Pharmaceuticals Announces Pricing Of Initial Public Offering
-
ACM Research to Participate in Upcoming Investor Conferences
-
EnviroLeach Technologies to Participate in Upcoming Investor Conferences
-
Seelos Therapeutics to Participate in Upcoming Investor Conferences in December
-
Seelos Therapeutics to Participate in Upcoming Investor Conferences in December
-
Biolase (BIOL) Prices 7.82M Share Common Offering at $0.5750/Sh; Announces Concurrent Private Placement of Convertible Preferred Shares

